FDA approves Sanofi’s Sarclisa Escena with wearable injector for multiple myeloma
The United States Food and Drug Administration (FDA) has approved Sanofi’s Sarclisa Escena for subcutaneous administration through the CirCLIQ on-body injector, creating the first FDA-authorised anticancer treatment that can be delivered using a wearable injector. The regulator approved the fixed 1,400-milligram dose on July 9, 2026 for several multiple myeloma treatment combinations already supported by
